The Food and Drug Administration will review MAP Pharmaceuticals Inc.’s experimental migraine drug Levadex, the Mountain View, Calif., company said. Levadex is an orally inhaled drug proposed to treat migraines in adults. The biopharmaceutical company focuses on developing new therapies to address patient needs in neurology.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help